166 related articles for article (PubMed ID: 37689735)
1. Phosphorylation at tyrosine 317 and 508 are crucial for PIK3CA/p110α to promote CRC tumorigenesis.
Wang T; Sun L; Chen C; Zhang Y; He B; Zhang Y; Wang Z; Xue H; Hao Y
Cell Biosci; 2023 Sep; 13(1):164. PubMed ID: 37689735
[TBL] [Abstract][Full Text] [Related]
2. The p110α/ΔNp63α complex mutations in triple-negative breast cancer: Potential targets for transcriptional-based therapies.
Ma W; Han X; Shasaltaneh MD; Hosseinifard H; Maghsoudloo M; Zhang Y; Weng Q; Wang Q; Wen Q; Imani S
Tumour Biol; 2023; 45(1):127-146. PubMed ID: 37980588
[TBL] [Abstract][Full Text] [Related]
3. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
Yip WK; Choo CW; Leong VC; Leong PP; Jabar MF; Seow HF
APMIS; 2013 Oct; 121(10):954-66. PubMed ID: 23992303
[TBL] [Abstract][Full Text] [Related]
4. Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway.
Chen Z; Wang C; Dong H; Wang X; Gao F; Zhang S; Zhang X
Mol Med; 2020 Jan; 26(1):14. PubMed ID: 32000660
[TBL] [Abstract][Full Text] [Related]
5. Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.
Fernandes MS; Melo S; Velho S; Carneiro P; Carneiro F; Seruca R
Oncotarget; 2016 Oct; 7(42):68546-68558. PubMed ID: 27602501
[TBL] [Abstract][Full Text] [Related]
6. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
[TBL] [Abstract][Full Text] [Related]
7. Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers.
Hutchinson KE; Chen JW; Savage HM; Stout TJ; Schimmoller F; Cortés J; Dent S; Harbeck N; Jacot W; Krop I; Trabucco SE; Sivakumar S; Sokol ES; Wilson TR
Genome Med; 2023 Apr; 15(1):28. PubMed ID: 37101291
[TBL] [Abstract][Full Text] [Related]
8. Increased Expression of Phosphatidylinositol 3-Kinase p110α and Gene Amplification of PIK3CA in Nasopharyngeal Carcinoma.
Yip WK; He PY; Abdullah MA; Yusoff S; Seow HF
Pathol Oncol Res; 2016 Apr; 22(2):413-9. PubMed ID: 26581613
[TBL] [Abstract][Full Text] [Related]
9. PI3-kinase p110α mediates β1 integrin-induced Akt activation and membrane protrusion during cell attachment and initial spreading.
Zeller KS; Idevall-Hagren O; Stefansson A; Velling T; Jackson SP; Downward J; Tengholm A; Johansson S
Cell Signal; 2010 Dec; 22(12):1838-48. PubMed ID: 20667469
[TBL] [Abstract][Full Text] [Related]
10. PTEN-deficient cancers depend on PIK3CB.
Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892
[TBL] [Abstract][Full Text] [Related]
11. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.
Rudd ML; Price JC; Fogoros S; Godwin AK; Sgroi DC; Merino MJ; Bell DW
Clin Cancer Res; 2011 Mar; 17(6):1331-40. PubMed ID: 21266528
[TBL] [Abstract][Full Text] [Related]
12. TRAF6 interacts with and ubiquitinates PIK3CA to enhance PI3K activation.
Wang Z; Liu Y; Huang S; Fang M
FEBS Lett; 2018 Jun; 592(11):1882-1892. PubMed ID: 29729098
[TBL] [Abstract][Full Text] [Related]
13. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.
Hao Y; Wang C; Cao B; Hirsch BM; Song J; Markowitz SD; Ewing RM; Sedwick D; Liu L; Zheng W; Wang Z
Cancer Cell; 2013 May; 23(5):583-93. PubMed ID: 23643389
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine phosphorylation sites at amino acids 239 and 240 of Shc are involved in epidermal growth factor-induced mitogenic signaling that is distinct from Ras/mitogen-activated protein kinase activation.
Gotoh N; Toyoda M; Shibuya M
Mol Cell Biol; 1997 Apr; 17(4):1824-31. PubMed ID: 9121430
[TBL] [Abstract][Full Text] [Related]
15. Mouse Models for Exploring the Biological Consequences and Clinical Significance of
Mitchell CB; Phillips WA
Biomolecules; 2019 Apr; 9(4):. PubMed ID: 31018529
[TBL] [Abstract][Full Text] [Related]
16. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
Elkabets M; Vora S; Juric D; Morse N; Mino-Kenudson M; Muranen T; Tao J; Campos AB; Rodon J; Ibrahim YH; Serra V; Rodrik-Outmezguine V; Hazra S; Singh S; Kim P; Quadt C; Liu M; Huang A; Rosen N; Engelman JA; Scaltriti M; Baselga J
Sci Transl Med; 2013 Jul; 5(196):196ra99. PubMed ID: 23903756
[TBL] [Abstract][Full Text] [Related]
17. Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function.
Yea SS; So L; Mallya S; Lee J; Rajasekaran K; Malarkannan S; Fruman DA
PLoS One; 2014; 9(6):e99486. PubMed ID: 24915189
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.
Ligresti G; Militello L; Steelman LS; Cavallaro A; Basile F; Nicoletti F; Stivala F; McCubrey JA; Libra M
Cell Cycle; 2009 May; 8(9):1352-8. PubMed ID: 19305151
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway.
Hu H; Zhu J; Zhong Y; Geng R; Ji Y; Guan Q; Hong C; Wei Y; Min N; Qi A; Zhang Y; Li X
Ann Transl Med; 2021 Mar; 9(5):410. PubMed ID: 33842631
[TBL] [Abstract][Full Text] [Related]
20. Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines.
Juvin V; Malek M; Anderson KE; Dion C; Chessa T; Lecureuil C; Ferguson GJ; Cosulich S; Hawkins PT; Stephens LR
PLoS One; 2013; 8(10):e75045. PubMed ID: 24124465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
